Cargando…
Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)
Urokinase-type plasminogen activator (uPA) is associated with cancer recurrence where the most evidence comes from studies in breast cancer. According to the European Organization for Research and Treatment of Cancer, uPA is considered one of the most prominent biomarkers for cancer recurrence and t...
Autores principales: | Santos, Nancy Dos, Habibi, Golareh, Wang, Michelle, Law, Jennifer H., Andrews, Heather N., Wei, Daniel, Triche, Timothy, Dedhar, Shoukat, Dunn, Sandra E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634623/ https://www.ncbi.nlm.nih.gov/pubmed/23645983 |
Ejemplares similares
-
QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model
por: Kalra, Jessica, et al.
Publicado: (2009) -
The autoactivation of human single-chain urokinase-type plasminogen activator (uPA)
por: Torres-Paris, Constanza, et al.
Publicado: (2023) -
Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation
por: Cunningham, Orla, et al.
Publicado: (2009) -
Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer
por: Asuthkar, Swapna, et al.
Publicado: (2013) -
Urokinase-type plasminogen activator (uPA) regulates invasion and matrix remodelling in colorectal cancer
por: Micalet, Auxtine, et al.
Publicado: (2023)